Claus Braestrup - Evotec SE Member of the Supervisory Board
EVOTF Stock | USD 10.18 3.65 26.39% |
Executive
Dr. Claus T. Braestrup, M.D., was Independent Member of the Supervisory Board of Evotec AG since June 12, 2013. He is Member of the Audit Committee at the Company. During his career, he gained experience from publicly traded international pharmaceutical companies as well as scientific and drug discovery qualifications. From 2003 to 2008, he served as President and CEO at H. Lundbeck AS, where he was head of research and development from 1998 to 2003. Previously, he served as head of preclinical drug research at Schering AG from 1994 to 1998, at Novo Nordisk AS as president of the Diabetes Care Division, President of its CNS Division and Vice President of pharmaceutical research and at Ferrosan AS as scientist in drug discovery from 1978 to 1984. He serves as Chairman of the Board of Saniona AB and as Member of the Board of Bavarian Nordic AS, Kastan ApS and Evolva SA. He holds a Masters degree in Chemical Engineering and is MS in Biochemistry. He is Doctor of Medical Science and former Adjunct Professor in Neuroscience at the University of Copenhagen. since 2013.
Age | 72 |
Tenure | 11 years |
Phone | 49 40 560 81 0 |
Web | https://www.evotec.com |
Evotec SE Management Efficiency
Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Bart Dunn | Collegium Pharmaceutical | N/A | |
Eiry Roberts | Neurocrine Biosciences | 54 | |
Malcolm LloydSmith | Neurocrine Biosciences | 62 | |
Margarida Duarte | Deciphera Pharmaceuticals LLC | N/A | |
Julie Cooke | Neurocrine Biosciences | 58 | |
Jane Sorensen | Neurocrine Biosciences | N/A | |
Michael MD | Ironwood Pharmaceuticals | 64 | |
Craig MD | Alkermes Plc | 56 | |
Jerad Seurer | Avadel Pharmaceuticals PLC | N/A | |
Matthew Abernethy | Neurocrine Biosciences | 44 | |
Max Reinhardt | Pacira Pharmaceuticals | 53 | |
Christopher MD | Collegium Pharmaceutical | N/A | |
Mark Elrod | Avadel Pharmaceuticals PLC | N/A | |
Dashyant Dhanak | Deciphera Pharmaceuticals LLC | 63 | |
Roy Winston | Pacira Pharmaceuticals | 57 | |
Selina Zhang | HUTCHMED DRC | N/A | |
David Ng | HUTCHMED DRC | N/A | |
Peter Norman | Alkermes Plc | N/A | |
Esq III | Pacira Pharmaceuticals | 50 | |
Samuel Parisi | Alkermes Plc | 49 | |
DO Ellis | Pacira Pharmaceuticals | 53 |
Management Performance
Return On Equity | -0.16 | |||
Return On Asset | -0.0012 |
Evotec SE Leadership Team
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthias Evers, Chief Board | ||
Werner Lanthaler, President of the Management Board, CEO | ||
Claus Braestrup, Member of the Supervisory Board | ||
Michael Shalmi, Member of the Supervisory Board | ||
Monika Conradt, Global HR | ||
Christian Dargel, EVP Compliance | ||
Mario Polywka, COO and Member of Management Board | ||
Anja Bosler, Principal Accounting | ||
Mary Tanner, Member of the Supervisory Board | ||
Volker Braun, VP ESG | ||
Roland Oetker, Deputy Chairman of the Supervisory Board | ||
Andreas Pinkwart, Member of the Supervisory Board | ||
Paul Herrling, Member of the Supervisory Board | ||
Colin Bond, CFO and Member of Management Board | ||
Cord Dohrmann, Chief Scientific Officer and Member of Management Board | ||
Iris LoewFriedrich, Member of the Supervisory Board | ||
Bernd Hirsch, Member of the Supervisory Board | ||
Enno Spillner, CFO, Member of the Management Board | ||
Elaine Sullivan, Member of the Supervisory Board | ||
Gabriele Hansen, Vice President Corporate Communications & Investor Relations | ||
MBA MBA, Chairman CEO | ||
Craig Johnstone, COO, Member of the Management Board | ||
Wolfgang Plischke, Chairman of the Supervisory Board |
Evotec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.16 | |||
Return On Asset | -0.0012 | |||
Profit Margin | (0.26) % | |||
Operating Margin | (0.01) % | |||
Current Valuation | 2.68 B | |||
Shares Outstanding | 176.95 M | |||
Shares Owned By Insiders | 9.86 % | |||
Shares Owned By Institutions | 66.12 % | |||
Price To Earning | 347.66 X | |||
Price To Book | 2.28 X |
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving against Evotec Pink Sheet
0.84 | TEVA | Teva Pharmaceutical | PairCorr |
0.42 | LRDG | Lord Global Corp | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Evotec Pink Sheet analysis
When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |